Immodulon has announced the appointment of Thomas O. Kleen as chief scientific officer of the Company, with immediate effect.
Thomas has over 15 years’ expertise working within the biotechnology and pharmaceutical industry. His strategic focus is on the monitoring of Cell Mediated Immunity and Bio-markers during cancer immunotherapy, inflammatory disease, vaccine development and detection of adverse immune reactions during drug development.
He has also designed immune monitoring technologies for companies and government institutions as well as advising on their appropriate use.
Dr Jaap Kampinga, chief executive of Immodulon, commented: “I am delighted to welcome Dr Kleen to the senior management team as our new Chief Scientific Officer. Thomas brings significant knowledge and strategic expertise in the development of cancer immunotherapies. He has a proven track record in supporting drug development which will be invaluable to Immodulon as we work to further advance Immodulon’s lead candidate, IMM-101.”